Introduction/Background There is a disparity in ovarian cancer outcomes in the UK compared to other European countries. The ovarian cancer feasibility pilot in 2020 identified disparities in treatment outcomes across the UK. BGCS Quality Indicators (QIs) were introduced to improve the standard ovarian cancer care. ESGO also provides QIs with a similar objective.

Methodology Retrospective audit of ovarian cancer debulking surgeries at CUH from 2019 to 2022. Cases were identified from combined MDT and pathology databases. Statistical analysis was performed with SPSS version 26.

Results The median overall age of the cohort was 64 (CI 62.7 - 63.9) years old. A total of 390 patients underwent surgery of which 57% were primary and 43% interval debulking over the 3-year period. Staging breakdown: Stage 1 – n=88, Stage 2 – n=45, Stage 3 – n=175, and Stage 4 - n=82. The MDT information of CA-125 was present in 96% of all debulking cases but CEA was missing in 38% of primary surgical cases. Complete cytoreduction was achieved in 58% of surgeries.

Conclusion The ovarian cancer BGCS and ESGO QIs provided useful measures to improve the standard of care at our institution. We have created more stringent MDT referral criteria and setup a prospective surgical database based on the audit results.

Disclosures No conflicts of interest to report.